Joint Infection Clinical Trial
Official title:
Oral vs Intravenous Antibiotics for Treatment of Periprosthetic Joint Infection
Management of periprosthetic joint infection (PJI) commonly includes 6 weeks of intravenous (IV) antibiotics after surgical treatment. However, there is little evidence to suggest that oral (PO) therapy results in worse outcomes. This study aims to determine whether or not PO antibiotics are non-inferior to IV antibiotics in treating PJI. The study is a multicenter, parallel-group, randomized (1 : 1), open-label, non-inferiority trial. The non-inferiority margin will be set at 10%. Adults with a clinical diagnosis of PJI according to the International Consensus Meeting (ICM) criteria who would ordinarily receive at least 6 weeks of antibiotics and have received ≤ 7 days of IV therapy from surgery will be included. A total of 308 participants will be centrally computer-randomized to PO or IV antibiotics to complete the first 6 weeks of therapy. Follow-on PO therapy will be permitted in either arm. The primary outcome is the proportion of participants experiencing treatment failure within 1 year. An associated cost-effectiveness evaluation including complications, resource utilization and quality-of-life data will be performed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05519007 -
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
|
N/A | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Recruiting |
NCT05341908 -
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
|
||
| Recruiting |
NCT03550911 -
Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
|
||
| Completed |
NCT04440631 -
Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Recruiting |
NCT05137314 -
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
|
Phase 1 | |
| Not yet recruiting |
NCT06293352 -
Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection
|
N/A | |
| Recruiting |
NCT04304885 -
Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
|
||
| Completed |
NCT03403608 -
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections
|
N/A | |
| Recruiting |
NCT03704766 -
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
|
N/A | |
| Completed |
NCT00974493 -
Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
|
Phase 4 | |
| Completed |
NCT03191292 -
Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection
|
N/A | |
| Recruiting |
NCT06191601 -
Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
|
||
| Completed |
NCT05804058 -
Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
|
||
| Completed |
NCT03426761 -
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
|
Phase 4 | |
| Enrolling by invitation |
NCT03713528 -
Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?
|
Phase 4 | |
| Completed |
NCT04948281 -
Joint Infection Following ACL Reconstruction
|
||
| Completed |
NCT06267287 -
Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period
|
||
| Terminated |
NCT03335592 -
Cost of Off-label Antibiotics in Osteoarticular Infections
|